Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau Farmaceutica's cash flow for dividends for the
three
months ended in Mar. 2026 was R$-3 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was R$-63 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Blau Farmaceutica's quarterly payment of dividends
increased
from Sep. 2025 (R$-25 Mil) to Dec. 2025 (R$-35 Mil) but then
declined
from Dec. 2025 (R$-35 Mil) to Mar. 2026 (R$-3 Mil).
Blau Farmaceutica's annual payment of dividends
declined
from Dec. 2023 (R$-66 Mil) to Dec. 2024 (R$-56 Mil) but then
increased
from Dec. 2024 (R$-56 Mil) to Dec. 2025 (R$-82 Mil).
Blau Farmaceutica Cash Flow for Dividends Related Terms
Blau Farmaceutica Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of R$-63 Mil mean?
Blau Farmaceutica (BSP:BLAU3) has a Cash Flow for Dividends of R$-63 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Blau Farmaceutica and its competitors.
Is Blau Farmaceutica's Cash Flow for Dividends too high?
Blau Farmaceutica's current Cash Flow for Dividends is R$-63 Mil. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Cash Flow for Dividends compare to ZTS and UTHR?
Blau Farmaceutica's Cash Flow for Dividends of R$-63 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Blau Farmaceutica and its competitors. Blau Farmaceutica's current Cash Flow for Dividends is R$-63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current Cash Flow for Dividends is R$-63 Mil. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Cash Flow for Dividends is R$-63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Cash Flow for Dividends: R$-63 Mil
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
